Cancer Molecular Diagnostics: On The Critical Path To Personalized Medicine

Main Category: Cancer / Oncology
Article Date: 23 Jul 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


The Healthcare practice at Frost & Sullivan is pleased to announce its 2008 Quarterly Analyst Briefing Presentation on the North American cancer molecular diagnostics market to be held on Thursday July 24, 2008 at 10:00 a.m. PDT.

The presentation will cover strategic insight into the U.S. cancer molecular diagnostics market and how the market correlates with growth in the world of personalized medicine. The briefing will examine the competitive dynamics of two main routes to get cancer molecular diagnostic tests to market - CLIA versus IVD models. It is crucial for any company or investor to examine the details of the rapid growth taking place in the fragmented space of the cancer molecular diagnostics market in order to exploit growth opportunities.

The briefing will benefit: clinical diagnostics companies and pharmaceutical companies, biotechnology companies, personalized medicine companies, companion diagnostics companies, investors and venture capital firms, life sciences research tools providers, platform technology providers, biomarker discovery companies, pharmacogenomics services providers, and contract research organizations. The briefing will highlight the critical questions that surround companion diagnostics and pharmacogenomicsyea.

"The regulatory environment around the cancer molecular diagnostics is still in flux," states Frost & Sullivan Senior Research Analyst Sudeep Basu, PhD. "While the near term benefit the adoption of a CLIA lab-based strategy are reaping, the long term view must be kept in perspective."

To participate, please email Stephanie Ochoa, Corporate Communications, at stephanie.ochoa@frost.com with the following information: your full name, title, company name, company telephone number, company e-mail address, city, state and country. Upon receipt of the above information, a registration link will be emailed to you. You may also register to receive a recorded version of the briefing at anytime by submitting the aforementioned contact details.

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit www.frost.com.

Article adapted by Medical News Today from original press release.
Visit our cancer / oncology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Frost & Sullivan. "Cancer Molecular Diagnostics: On The Critical Path To Personalized Medicine." Medical News Today. MediLexicon, Intl., 23 Jul. 2008. Web.
11 Feb. 2012. <http://www.medicalnewstoday.com/releases/115820.php>

APA
Frost & Sullivan. (2008, July 23). "Cancer Molecular Diagnostics: On The Critical Path To Personalized Medicine." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/115820.php.

Please note: If no author information is provided, the source is cited instead.


Cancer / Oncology

What is Cancer?

Cancer is a class of diseases characterized by out-of-control cell growth. There are over 100 different types of cancer, and each is classified by the type of cell that is initially affected. Read more...

Most Popular Articles



Follow Our Cancer News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cancer / Oncology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »